Stock fact sheet · data as of
Chemomab Therapeutics Ltd. (CMMB): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · Israel · ADR · Speculative / Distressed
Is CMMB undervalued?
CMMB closed at 1.29 on 16 Oct 2026, 17% below the GLS average fair value of 1.56 from 1 models (1 of them above the price). That is a moderate margin of safety: the stock passes the "below fair value" rule of the Sunday Scan, and the Wheel Score gives it 20 of the 25 Value points.
The average is built from just 1 models (DCF) - the rest returned nothing because an input they need (dividends, free cash flow, book value) is zero or negative - so treat it with more caution than usual.
The nightly engine files CMMB under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for CMMB
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 1.56 | +21% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | 1.94 | +50% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 0.0000 | -100% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Chemomab Therapeutics Ltd. scores only 0 of 9 on the Piotroski F-score, which fails the Sunday Scan's "6 or more" rule. A reading this low means several of the basic tests - positive earnings, positive operating cash flow, falling debt, no new share issuance - are not met. A GLS Moat score of 1.6/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.
Returns on capital are thin or negative - ROIC -72.9%, ROE -72.9%, ROA -65.1% - with debt at 0.00 times equity and negative free cash flow.
Chemomab Therapeutics Ltd. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.
Institutional ownership scores 1/10, insider activity 7/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 0 / 9 | ROIC | -72.9% |
|---|---|---|---|
| GLS Moat | 1.6 / 10 | ROE | -72.9% |
| Debt / equity | 0.00 | ROA | -65.1% |
| Free-cash-flow yield | -141.3% | Payout ratio | 0% |
| Institutions | 1 / 10 | Insiders · Congress | 7 · 5 / 10 |
Wheel Score 28: No options
No options are listed on Chemomab Therapeutics Ltd. in our nightly snapshot. The Wheel Score is therefore capped at 39 (it reads 28) and the stock is left out of every options screen; the fair value and health figures above are still useful for a plain stock position.
Volume runs at 22k shares a day on a market cap of $8M, with a beta of 0.66 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 6 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 20 / 25 | 17% margin of safety | |
| Health | 0 / 20 | Piotroski 0/9 | |
| Moat | 2 / 15 | moat 1.6/10 | |
| Premium | 0 / 20 | no option data | |
| Stability | 6 / 20 | 22k shares/day, $8M cap, beta 0.66 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 6 Nov 2026 (before the open), 21 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to Chemomab Therapeutics Ltd. by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| KPTI Karyopharm Therapeutics Inc. | 0.3508 | - | - | 37Weak | $8M |
| APRE Aprea Therapeutics, Inc. | 0.6176 | 2.14 | +71% | 38No options | $8M |
| BOLT Bolt Biotherapeutics, Inc. | 4.24 | - | - | 27No options | $8M |
| XCUR Exicure, Inc. | 1.21 | 0.3541 | -242% | 4No options | $8M |
| QNRX Quoin Pharmaceuticals, Ltd. | 4.10 | 2,547.50 | +100% | 35No options | $8M |
| ADIL Adial Pharmaceuticals, Inc. | 3.14 | 7.98 | +61% | 37No options | $8M |
| CURX Curanex Pharmaceuticals Inc Common Stock | 4.83 | 3.26 | -48% | 13No options | $8M |
| CNSP CNS Pharmaceuticals, Inc. | 5.18 | 7.71 | +33% | 35No options | $8M |
| SNTI Senti Biosciences, Inc. | 0.2408 | - | - | 23No options | $7M |
| SNGX Soligenix, Inc. | 0.3407 | 1.27 | +73% | 35No options | $7M |
| LTRN Lantern Pharma Inc. | 0.6668 | - | - | 27Weak | $9M |
| ICU SeaStar Medical Holding Corporation | 3.06 | 3.09 | +1% | 29No options | $9M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about CMMB
Is CMMB undervalued right now?
By the GLS models, moderately: at 1.29 the stock trades 17% below the average fair value of 1.56 (data as of 16 Oct 2026).
What is the Wheel Score of CMMB and what does it mean?
CMMB has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".
What is the GLS fair value for CMMB?
1.56 per share as of 16 Oct 2026 - the simple average of the 1 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Chemomab Therapeutics Ltd. report earnings next?
The next earnings report is due on 6 Nov 2026 (before the open), 21 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does CMMB have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on CMMB, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.